Cara Therapeutics Inc
F:69C
Cara Therapeutics Inc
F:69C
Price:
1.04
EUR
11.23%
Market Closed
Market Cap:
€56.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
C
|
Cara Therapeutics Inc
F:69C
|
US |
|
S
|
Spacsphere Acquisition Corp
NASDAQ:SSAC
|
US |
|
Alterity Therapeutics Ltd
F:PBN
|
AU |
|
C
|
Colfax Corp
F:C52
|
US |
|
A
|
Admiralty Resources NL
XMUN:AHS
|
AU |
|
T
|
Texwinca Holdings Ltd
F:TXW
|
HK |
|
I
|
Invion Ltd
F:7C8
|
AU |
|
C
|
Clean Seas Seafood Ltd
OSE:CSS
|
AU |
|
S
|
Sirtec International Co Ltd
TPEX:5356
|
TW |
|
Goldhaven Resources Corp
F:4QS
|
CA |
|
Valion Bio Inc
NASDAQ:VBIO
|
US |
|
A
|
Aspermont Ltd
F:00W
|
AU |
|
W
|
Wereldhave NV
F:WER
|
NL |
|
SponsorsOne Brands Inc
F:5SO
|
CA |
|
S
|
Safestay PLC
F:5RI
|
UK |
|
E
|
East Africa Metals Inc
OTC:EFRMF
|
CA |
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 69C's stock price target?
Not Available
69C does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for Cara Therapeutics Inc?
Projected CAGR
39%
39%
Over the last 8 years, the compound annual growth rate for Revenue has been 70%. The projected CAGR for the next 3 years is 39%.
